These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37965584)

  • 1. Safety and Efficacy Analysis of PD-1 Inhibitors in Combination with Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer: A Real-World, Single-Center Study.
    Chen Z; He Y; Ding C; Chen J; Gu Y; Xiao M; Li Q
    Onco Targets Ther; 2023; 16():923-935. PubMed ID: 37965584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
    Shui L; Cheng K; Li X; Shui P; Zhou X; Li J; Yi C; Cao D
    BMC Cancer; 2020 Jul; 20(1):636. PubMed ID: 32646394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis.
    Schlick K; Gantschnigg A; Seymer A; Huemer F; Greil R; Weiss L
    Cancer Med; 2023 Aug; 12(16):16997-17004. PubMed ID: 37537780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
    Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficiency and toxicity of nab-paclitaxel and camrelizumab in the second or above line treatment of advanced non-small cell lung cancer: a retrospective cohort study.
    Yin C; Zou GR; He Y; Li J; Yan HW; Su Z; Cao XL; Li XB
    J Thorac Dis; 2023 Apr; 15(4):1838-1847. PubMed ID: 37197501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort.
    Wu H; Huang N; Zhao C; Hu X; Da L; Huang W; Shen Y; Xiong F; Zhang C
    Ann Transl Med; 2022 Mar; 10(6):294. PubMed ID: 35433955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.
    Fernández A; Salgado M; García A; Buxò E; Vera R; Adeva J; Jiménez-Fonseca P; Quintero G; Llorca C; Cañabate M; López LJ; Muñoz A; Ramírez P; González P; López C; Reboredo M; Gallardo E; Sanchez-Cánovas M; Gallego J; Guillén C; Ruiz-Miravet N; Navarro-Pérez V; De la Cámara J; Alés-Díaz I; Pazo-Cid RA; Carmona-Bayonas A
    BMC Cancer; 2018 Nov; 18(1):1185. PubMed ID: 30497432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1 blockade combined with gemcitabine plus nab-paclitaxel is superior to chemotherapy alone in the management of unresectable stage III/IV pancreatic cancer: a retrospective real-world study.
    Cheng D; Hu J; Wu X; Wang B; Chen R; Zhao W; Fang C; Ji M
    Front Oncol; 2023; 13():1281545. PubMed ID: 37965469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of gemcitabine plus S-1
    Zhu Z; Tang H; Ying J; Cheng Y; Wang X; Wang Y; Bai C
    Cancer Biol Med; 2023 Aug; 20(10):765-78. PubMed ID: 37646237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study.
    Queck A; Elango S; Koch C; Walter D; Schmidt J; Trebicka J; Trojan J; Pession U; Finkelmeier F; Waidmann O
    Oncol Res Treat; 2022; 45(3):79-87. PubMed ID: 34875671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
    Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
    BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer.
    Lu C; Zhu Y; Kong W; Yang J; Zhu L; Wang L; Tang M; Chen J; Li Q; He J; Li A; Qiu X; Gu Q; Chen D; Meng F; Liu B; Qiu Y; Du J
    Front Oncol; 2022; 12():879661. PubMed ID: 36059628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer.
    Wang J; He Y; Zhang B; Lv H; Nie C; Chen B; Xu W; Zhao J; Cheng X; Li Q; Tu S; Chen X
    Front Oncol; 2022; 12():924149. PubMed ID: 35719979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial.
    Huffman BM; Basu Mallick A; Horick NK; Wang-Gillam A; Hosein PJ; Morse MA; Beg MS; Murphy JE; Mavroukakis S; Zaki A; Schlechter BL; Sanoff H; Manz C; Wolpin BM; Arlen P; Lacy J; Cleary JM
    JAMA Netw Open; 2023 Jan; 6(1):e2249720. PubMed ID: 36602796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy.
    Zhang F; Huang D; Zhao L; Li T; Zhang S; Zhang G; Yuan F; Zhang J; Zhang Y; Zhao Z; Cui L; Zhao J; Wang G; Cai S; Bai Y; Wang J; Hu Y
    Ther Adv Med Oncol; 2020; 12():1758835920936882. PubMed ID: 32670420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study.
    Chang C; Meng L; Li X; Cheng K; Yi C; Peng B; Ma J; Cao D
    Cancer Control; 2022; 29():10732748221141233. PubMed ID: 36423238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study.
    Zhang F; Wang Y; Yang F; Zhang Y; Jiang M; Zhang X
    Cancer Manag Res; 2022; 14():535-546. PubMed ID: 35173487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study.
    Chen S; Li J; Dong A; Liu Z; Zhu M; Jin M; Wei G; Wu S; Wang Y; Chen Y; Peng Z
    J Hematol Oncol; 2023 Mar; 16(1):26. PubMed ID: 36941671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-label, Phase I Study of Nivolumab Combined with
    Wainberg ZA; Hochster HS; Kim EJ; George B; Kaylan A; Chiorean EG; Waterhouse DM; Guiterrez M; Parikh A; Jain R; Carrizosa DR; Soliman HH; Lila T; Reiss DJ; Pierce DW; Bhore R; Banerjee S; Lyons L; Louis CU; Ong TJ; O'Dwyer PJ
    Clin Cancer Res; 2020 Sep; 26(18):4814-4822. PubMed ID: 32554514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.